Literature DB >> 23444210

Comparison of fluorescence in situ hybridization, NMP22 bladderchek, and urinary liquid-based cytology in the detection of bladder urothelial carcinoma.

Hong-xia Li1, Ming-rong Wang, Huan Zhao, Jian Cao, Chang-ling Li, Qin-Jing Pan.   

Abstract

The aim of this study is to evaluate the diagnostic values of the fluorescence in situ hybridization (FISH), NMP22 BladderChek, and liquid-based cytology (LBC) in the detection of bladder urothelial carcinoma (UC). Consecutive voided urine samples were collected from 138 in-house patients with a variety of urologic conditions and 37 healthy individuals as negative controls. FISH, NMP22 BladderChek, and LBC were performed on the specimens. All three tests were evaluated independently in a blinded fashion. In all, 104 out of the 175 patients enrolled in this study had histologically proven UC. LBC, FISH, and NMP22 BladderChek were successfully performed on 175, 149, and 119 cases, respectively. The three tests revealed overall sensitivities of 73.1%, 86.5%, and 67.6%, respectively. FISH was more sensitive than LBC (P=0.022) and NMP22 BladderChek (P=0.004). Combination of all the tests yielded a superior sensitivity of 96.7% compared with LBC (P<0.001), NMP22 BladderChek (P<0.001), and FISH (P=0.016), with the specificity only decreased slightly. Sensitivities of the three tests enhanced significantly with increasing UC grade (P<0.05). The positive rates of FISH and NMP22 BladderChek in equivocal cytologic diagnoses were 85.7% and 61.9% in UC, and 37.5% and 50.0% in non-UC (FISH: P=0.021; NMP22 BladderChek: P=0.683). FISH was more sensitive than LBC and NMP22 BladderChek. FISH had the ability to clarify equivocal cytologic diagnoses. Combination of all three tests showed an improvement in the sensitivity compared to any single test alone in detecting UC with the specificity slightly decreased.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  FISH; NMP22 BladderChek; liquid-based Cytology; urothelial carcinoma

Mesh:

Year:  2013        PMID: 23444210     DOI: 10.1002/dc.22969

Source DB:  PubMed          Journal:  Diagn Cytopathol        ISSN: 1097-0339            Impact factor:   1.582


  7 in total

1.  Prospective evaluation of fluorescence in situ hybridization for diagnosing urothelial carcinoma.

Authors:  Tianhai Lin; Zhenhua Liu; Liangren Liu; Lu Yang; Ping Han; Peng Zhang; Qiang Wei
Journal:  Oncol Lett       Date:  2017-03-27       Impact factor: 2.967

Review 2.  Diagnostic Value of Liquid-Based Cytology in Urothelial Carcinoma Diagnosis: A Systematic Review and Meta-Analysis.

Authors:  You Luo; Dong-Li She; Hu Xiong; Li Yang; Sheng-Jun Fu
Journal:  PLoS One       Date:  2015-08-04       Impact factor: 3.240

3.  Is liquid-based cytology an alternative to conventional cytology for detection of malignant cells in urine of bladder cancer? Eastern Indian prospective observational study.

Authors:  Kunal Kapoor; Chhanda Datta; Dilip Kumar Pal
Journal:  Turk J Urol       Date:  2019-09-01

4.  Comparison of the diagnostic performance of fluorescence in situ hybridization (FISH), nuclear matrix protein 22 (NMP22), and their combination model in bladder carcinoma detection: a systematic review and meta-analysis.

Authors:  Qindong Liang; Guangjie Zhang; Wuxian Li; Jing Wang; Shangchun Sheng
Journal:  Onco Targets Ther       Date:  2018-12-31       Impact factor: 4.147

Review 5.  Architectural aspects of cell-blocks as small biopsies.

Authors:  Swati Satturwar; Liron Pantanowitz
Journal:  Cytojournal       Date:  2021-03-04       Impact factor: 2.091

6.  Is Diagnosis of Low-Grade Urothelial Carcinoma Possible in Urine Cytology?

Authors:  Saloni Bansal; Saleem Pathuthara; Santhosh Joseph; Swati Dighe; Santosh Menon; Sangeeta B Desai
Journal:  J Cytol       Date:  2021-05-11       Impact factor: 1.000

7.  Evaluation of the NMP22 BladderChek test for detecting bladder cancer: a systematic review and meta-analysis.

Authors:  Zijie Wang; Hongliang Que; Chuanjian Suo; Zhijian Han; Jun Tao; Zhengkai Huang; Xiaobin Ju; Ruoyun Tan; Min Gu
Journal:  Oncotarget       Date:  2017-10-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.